Thermo Fisher Scientific Inc. (Massachusetts, USA) has opened a new biomanufacturing facility in Chelmsford, Massachusetts. The $160 million, 85,000-square-foot facility will help meet growing demand for the biologic materials needed to produce vaccines and breakthrough therapies for cancer and other diseases. This new site is part of Thermo Fisher’s $650 million multi-year investment to expand its bioprocessing production capabilities.
“This market continues to grow, and the world’s leading biopharmaceutical companies depend on our technologies, services, and expertise to help deliver life-changing therapies to patients,” said Jean Luo, VP and General Manager, Purification and Pharma Analytics, Thermo Fisher Scientific.
The technologies produced at the Chelmsford site are used in the purification process of developing biotherapeutics and vaccines. These products help save time and reduce costs so that new treatments can reach more patients faster.
“The Chelmsford site will help us provide our customers with the critical resin materials they need as they scale up production and bring new innovations to market,” continued Luo. “This ultimately helps ensure more patients get the treatments they need faster.”
When fully staffed, the Chelmsford site will employ up to 250 people and will be part of Thermo Fisher’s global bioprocessing supply network.
For more information, please visit: www.thermofisher.com
The Next Frontier for Mass Spectrometry: Maximizing Ion Utilization
January 20th 2025In this podcast, Daniel DeBord, CTO of MOBILion Systems, describes a new high resolution mass spectrometry approach that promises to increase speed and sensitivity in omics applications. MOBILion recently introduced the PAMAF mode of operation, which stands for parallel accumulation with mobility aligned fragmentation. It substantially increases the fraction of ions used for mass spectrometry analysis by replacing the functionality of the quadrupole with high resolution ion mobility. Listen to learn more about this exciting new development.
Using Chromatography to Explore Fluorescent Bioactive Compounds in the Coelomic Fluid of Earthworms
February 6th 2025A study aiming to identify fluorescent bioactive compounds in the coelomic fluid of earthworms, as well as to investigate their structural and functional characteristics for possible use in biomedical applications, utilized a variety of chromatographic techniques.
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.